Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424758 | 0.87 | NR3C1 (0.42) | NR3C1JAK2JAK3TRPV1P2RX7 | |
| SCHEMBL3428145 | 0.66 | NR3C1 (0.61) | NR3C1 | |
| SCHEMBL5471017 | 0.65 | KDM4C (0.33) | TRPV1KDM4C | |
| SCHEMBL5474864 | 0.65 | PTGDR2 (0.35) | TRPV1P2RX7KDM4C | |
| SCHEMBL3427700 | 0.65 | NR3C1 (0.45) | NR3C1 | |
| SCHEMBL5477201 | 0.65 | TRPV1 (0.31) | NR3C1TRPV1KDM4C | |
| SCHEMBL6017520 | 0.64 | NR3C1 (0.40) | NR3C1 | |
| SCHEMBL5479489 | 0.64 | KDM4C (0.38) | JAK2TRPV1KDM4C | |
| SCHEMBL15819872 | 0.64 | HTR2C (0.40) | TRPV1KDM4C | |
| SCHEMBL10244128 | 0.64 | ADRA2A (0.38) | TRPV1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727813-A1 | 2-PROPANOL AND 2-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-12-06 | — | — | EP | claimed |
| WO-2005090336-A1 | 2-PROPANOL AND 2-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203128-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | claimed |
| US-7795272-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795272-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795272-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20050203128-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203128-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885JAK2 1143/4885JAK3 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.